These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
287 related items for PubMed ID: 15280937
1. Economic cost of community-acquired pneumonia in New Zealand adults. Scott G, Scott H, Turley M, Baker M. N Z Med J; 2004 Jun 18; 117(1196):U933. PubMed ID: 15280937 [Abstract] [Full Text] [Related]
2. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US. Raut M, Schein J, Mody S, Grant R, Benson C, Olson W. Curr Med Res Opin; 2009 Sep 18; 25(9):2151-7. PubMed ID: 19601711 [Abstract] [Full Text] [Related]
3. Economic burden of schizophrenia: empirical analyses from a survey in Thailand. Phanthunane P, Whiteford H, Vos T, Bertram M. J Ment Health Policy Econ; 2012 Mar 18; 15(1):25-32. PubMed ID: 22611090 [Abstract] [Full Text] [Related]
4. Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin. Signorovitch JE, Sheng Duh M, Sengupta A, Gu A, Grant R, Raut M, Mody SH, Schein J, Fisher AC, Ng D. Curr Med Res Opin; 2010 Feb 18; 26(2):355-63. PubMed ID: 19995325 [Abstract] [Full Text] [Related]
5. Economic cost to New Zealand of foodborne infectious disease. Scott WG, Scott HM, Lake RJ, Baker MG. N Z Med J; 2000 Jul 14; 113(1113):281-4. PubMed ID: 10935568 [Abstract] [Full Text] [Related]
6. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis. Ye X, Sikirica V, Schein JR, Grant R, Zarotsky V, Doshi D, Benson CJ, Riedel AA. Clin Ther; 2008 Feb 14; 30(2):358-71. PubMed ID: 18343274 [Abstract] [Full Text] [Related]
10. The costs of not treating hepatitis C virus infection in injecting drug users in New Zealand. Sheerin IG, Green FT, Sellman JD. Drug Alcohol Rev; 2003 Jun 14; 22(2):159-67. PubMed ID: 12850902 [Abstract] [Full Text] [Related]
13. The economic burden of prostate cancer, California, 1998. Max W, Rice DP, Sung HY, Michel M, Breuer W, Zhang X. Cancer; 2002 Jun 01; 94(11):2906-13. PubMed ID: 12115378 [Abstract] [Full Text] [Related]
14. The cost of campylobacteriosis in New Zealand in 1995. Withington SG, Chambers ST. N Z Med J; 1997 Jun 27; 110(1046):222-4. PubMed ID: 9236803 [Abstract] [Full Text] [Related]
15. Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis. Rozenbaum MH, Mangen MJ, Huijts SM, van der Werf TS, Postma MJ. Vaccine; 2015 Jun 22; 33(28):3193-9. PubMed ID: 25981488 [Abstract] [Full Text] [Related]
16. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, Bridges CB. Vaccine; 2007 Jun 28; 25(27):5086-96. PubMed ID: 17544181 [Abstract] [Full Text] [Related]
17. Estimates of the direct cost per case and overall burden of trichomoniasis for the employer-sponsored privately insured women population in the United States, 2001 to 2005. Owusu-Edusei K, Tejani MN, Gift TL, Kent CK, Tao G. Sex Transm Dis; 2009 Jun 28; 36(6):395-9. PubMed ID: 19556934 [Abstract] [Full Text] [Related]
18. Economic burden of sexually transmitted infections: incidence and direct medical cost of Chlamydia, gonorrhea, and syphilis among Illinois adolescents and young adults, 2005-2006. Pultorak E, Wong W, Rabins C, Mehta SD. Sex Transm Dis; 2009 Oct 28; 36(10):629-36. PubMed ID: 19955874 [Abstract] [Full Text] [Related]